Benefits and Barriers to Use of Continuous Glucose Monitoring 24 Weeks Following Hospital Discharge
Authors' conclusion
HbA1c improved from baseline to 24 weeks among participants, regardless of continued CGM use. However, discontinuation was common, with financial barriers representing the predominant obstacle
Study context
- Population
- Hospitalized patients with insulin-requiring T2D (HbA1c > 8.0%) who received study-provided continuous glucose monitoring (CGM) for 12 weeks postdischarge57 with 24-week data
- Participants
- 108 patients
- Exposure
- CGM continuation vs discontinuation through usual care after study-provided CGM
- CGM usersn = 17
- Outcome
- CGM continuation, glycemic parameters, health care utilization and patient-reported barriers
- Follow-up
- 24 weeks
Methodological details12-week observational follow-up, 66 completed 12 week assessments; 59 were using CGM
- 12-week observational follow-up
- 66 completed 12 week assessments; 59 were using CGM
Main finding
As reported in the abstract
CGM continuation
Participants with 24-week data who maintained CGM use
17 of 57
Observational data: associations, not effects.
Further findings
Cost and insurance barriers
P = 0.007
- Cost and insurance barriers — Most reported challenge overall
- 46%
Median HbA1c, baseline to 24 weeks (all participants)
- Baseline median HbA1c
- 11.6% [IQR 10.0 to 13.4]
- 24-week median HbA1c
- 7.4% [IQR 6.7 to 9.5]
- In mmol/mol
- 103 to 57 mmol/mol
- Change from baseline
- P < 0.0001
- Similar reductions among users and nonusers
TIR (70 to 180 mg/dL) among CGM users · 12 to 24 weeks
- Median TIR 12 weeks to 24 weeks
- 43% to 62%
- Change
- P = 0.66
TAR (> 180 mg/dL) among CGM users · 12 to 24 weeks
- TAR 12 weeks to 24 weeks
- 57% to 37%
- Change
- P = 0.67
Original publication
Benefits and Barriers to Use of Continuous Glucose Monitoring 24 Weeks Following Hospital Discharge. Endocr Pract. Published 17 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →